AtriCure (NSDQ:ATRC) said yesterday that it closed the $99 million cash-and-stock buyout of cardiac ablation device maker nContact. Morrisville, N.C.-based nContact makes a system that’s designed to combine vacuum suction, perfusion and radiofrequency ablation to improve contact between cardiac tissue and the device. The company is running a U.S. investigational device exemption trial, comparing its Convergent procedure using the […]
nContact Inc.
AtriCure picks up MIS cardiac company nContact
AtriCure (NSDQ:ATRC) said yesterday it bought cardiac-focused medical device developer nContact for approximately $99 million in shares of common stock and up front cash. The sale was funded with an upfront payment of approximately 3.7 million shares of AtriCure at $24.60 per share and $8 million in cash up front. The purchase also includes up to $50 million […]
Biolase CEO succession continues | Personnel Moves
Biolase (NSDQ:BIOL) said earlier this month that CEO Jeffery Nugent has resigned from both his position as CEO and the board of directors, effective July 12, to be replaced by Harold Flynn. Irvine, Calif.-based Biolase picked up Flynn, the former president of Zimmer Dental (NYSE:ZMH), in May to replace Nugent, who the company said had stepped in to […]
Atrial fibrillation: nContact wins FDA clearance for cardiac device
nContact said it’s received FDA clearance for modifications made to its cardiac ablation device.
The Research Triangle Park, N.C.-based device medical device company won 510(k) clearance from the federal watchdog agency for the next generation of its VisiTrax cardiac ablation device, EPi-Sense. The company says this product includes new sensors, generating electrical feedback to assist electrophysiologists with device positioning during cardiac ablation procedures.
iRobot invests $6M into telemedicine company | Funding Roundup
iRobot Corp. (NSDQ: IRBT), famous for their Roomba automated cleaning robots, invested $6 million and launched an extended partnership with InTouch Health, which develops telemedicine systems for providing remote health care.
The venture builds on an existing relationship that the companies announced last summer, under which the companies engaged in a development and licensing agreement.
Optos gains on Project Daytona FDA clearance | MassDevice.com Regulatory Roundup
Shares of Optos plc (LSE:OPTS) gained 6.4 percent after the company announced that the FDA granted 510(k) clearance in the U.S. for its Project Daytona retinal scanning device.
The British ophthalmology device maker’s stock closed at £1.62 today (about $2.64), up about 15 cents since August 25, the day before the clearance announcement, when OPTS shares closed at £1.52 ($2.49) on the London Stock Exchange.
DePuy lands 510(k) for knee implant customization system | Regulatory Roundup
DePuy Orthopaedics Inc. landed clearance for its TruMatch surgical customization system for use with its Sigma fixed-bearing knee replacement device.
That means the Warsaw, Ind.-based Johnson & Johnson (NYSE:JNJ) subsidiary no longer has to worry about the FDA’s past warnings over illegal marketing of the device on its website.
nContact lops off ‘Surgical’ to reflect less invasive tech
nContact Surgical Inc. is now nContact Inc.
The Morrisville, N.C.-based cardiac device manufacturer said its new name represents a move towards less invasive, endoscopic approaches for treating irregular heartbeat with epicardial ablation. The company’s surgical tools allow cardiologists to treat arrhythmias through a small midline abdominal incision, according to the company.
nContact Surgical raises $16 million Series D round
Research Triangle Park, N.C.-based medical device maker nContact Surgical Inc. raised $16 million for its endoscopic cardiac ablation system that could enable doctors to treat the most difficult atrial fibrillation patients.
